Evidence map›Paper›PMID 28376458›Full record

ArticleAnnals of family medicine2017

Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.

Steven P Dehmer, Michael V Maciosek, Amy B LaFrance, Thomas J Flottemesch

Open access · diamondAbstract read
In one paragraph

Article in Annals of family medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Steven P DehmerHealthPartners Institute, Minneapolis, Minnesota steven.p.dehmer@healthpartners.com.
Michael V MaciosekHealthPartners Institute, Minneapolis, Minnesota.
Amy B LaFranceHealthPartners Institute, Minneapolis, Minnesota.
Thomas J FlottemeschHealthPartners Institute, Minneapolis, Minnesota.
HealthPartners · US

Funding

A NATIONAL COALITION TO ENHANCE STD/HIV PREVENTION THROUGH PROMOTION OF A HOLISTIH25PS003610 · PS · PARTNERSHIP FOR PREVENTION · PI KRISTENSEN, ALYSON · 2011 to 2015
$4.7M
NCHHSTP CDC HHS H25 PS003610
6 · The paper itself

Abstract

purposeOur aim was to update estimates of the health and economic impact of clinical services recommended for the primary prevention of cardiovascular disease (CVD) for the comparative rankings of the National Commission on Prevention Priorities, and to explore differences in outcomes by sex and race/ethnicity.

methodsWe used a single, integrated, microsimulation model to generate comparable results for 3 services recommended by the US Preventive Services Task Force: aspirin counseling for the primary prevention of CVD and colorectal cancer, screening and treatment for lipid disorders (usually high cholesterol), and screening and treatment for hypertension. Analyses compare lifetime outcomes from the societal perspective for a US-representative birth cohort of 100,000 persons with and without access to each clinical preventive service. Primary outcomes are health impact, measured by the net difference in lifetime quality-adjusted life years (QALYs), and cost-effectiveness, measured in incremental cost per QALY or cost savings per person in 2012 dollars. Results are also presented for population subgroups defined by sex and race/ethnicity.

resultsHealth impact is highest for hypertension screening and treatment (15,600 QALYs), but is closely followed by cholesterol screening and treatment (14,300 QALYs). Aspirin counseling has a lower health impact (2,200 QALYs) but is found to be cost saving ($31 saved per person). Cost-effectiveness for cholesterol and hypertension screening and treatment is $33,800 per QALY and $48,500 per QALY, respectively. Findings favor hypertension over cholesterol screening and treatment for women, and opportunities to reduce disease burden across all services are greatest for the non-Hispanic black population.

conclusionsAll 3 CVD preventive services continue to rank highly among other recommended preventive services for US adults, but individual priorities can be tailored in practice by taking a patient's demographic characteristics and clinical objectives into account.

Indexed as

Cost-Benefit AnalysisAdolescentAdultAgedAspirinColorectal NeoplasmsCounselingEthnicityFemaleHumansHypercholesterolemiaHypertensionMaleMass ScreeningMiddle AgedPrimary PreventionAspirinaspirinblood pressure, highCardiovascular diseasescholesterolcost-effectivenesshypertensionlipid disordersmass screeningprimary prevention

Identifiers

PMID28376458
PMCPMC5217841
OpenAlexW2571840362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.